Fairmount Funds Management LLC sold $399.7M of Spyre Therapeutics (SYRE)

Executed Jun 23, disclosed Jun 23, the same day.

Value, as filed

$399.7M

4,684,781 sh × $85.31

Executed

Jun 23

the trade date, as filed

Disclosed

Jun 23

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

FL Fairmount Funds Management LLC Director profile →

Fairmount Funds Management LLC (Director) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (6 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 6 priced purchase filings, the average 21-session return was +5.9% from execution and +8.5% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.

The name

SYRE

Spyre Therapeutics, Inc. SYRE · Healthcare · 29 filings in 24 months ticker →

Healthcare · Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→